Eiger BioPharmaceuticals, Inc. (EIGR) saw its loss widen to $12.77 million, or $1.53 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $7.06 million, or $25.78 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $12.91 million, compared with an operating loss of $6.71 million in the previous year period.
"We believe that 2016, Eiger's first year as a publicly traded company, was a year of significant accomplishment and advancement," said David Cory, president and chief executive officer of Eiger BioPharmaceuticals. "We advanced our pipeline of five Phase 2 programs across four therapeutically diverse orphan diseases spanning international clinical sites. We believe that these achievements have moved us closer to our goal of building a leading biotechnology company, and delivering value to patients and shareholders. We look forward to another year of accomplishment in 2017 as our pipeline matures, we anticipate advancement toward important Phase 2 data read-outs, and we will continue to pursue multiple shots on goal for clinical and regulatory success."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
